Roche under fire again: Mylan launches Herceptin copycat in latest blow to blockbuster trio

herceptin
Mylan said Herceptin biosim Ogivri would launch at a "competitive discount." (Roche)

Much has been made of the challenges Roche's blockbuster oncology troika faces with U.S. biosimilars hitting the market in quick succession. So far, those challengers haven't made much of a dent in Roche's sales stateside––but a new contestant could help tip the scales.

Mylan and Biocon have launched their Herceptin copy, Ogivri, in the U.S., making it the second biosim on the market for Roche's blockbuster breast and stomach cancer drug. 

Mylan said in a release that Ogivri would hit the market at a "competitive discount" to Herceptin but did not disclose the list price for its 420-milligram and 150-milligram vials. 

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

"With regulatory approval for our biosimilar (Herceptin) in more than 80 countries worldwide, we are bringing vast global biosimilars experience to the U.S. and look forward to continuing our work with all stakeholders in the healthcare system to reduce costs, improve access and advance care," Mylan President Rajiv Malik said in a statement. 

RELATED: Say hello to Roche's worst-case scenario: Teva's Rituxan biosim set to launch in U.S.

Suggested Articles

Incyte and Novartis' Jakafi is eying a nod in chronic graft vs. host disease—and it may just have the data to get it done.

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

News of an FDA plant inspection for a Macrogenics drug boosted investor confidence in BMS' ability to meet its year-end deadline for liso-cel.